Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 5:04 AM
Ignite Modification Date:
2025-12-25 @ 5:04 AM
NCT ID:
NCT00002418
Eligibility Criteria:
Inclusion Criteria
You may be eligible for this study if you:
* Are at least 18 years old.
* Are HIV-positive.
* Have experienced treatment failure on a previous anti-HIV drug combination that contained at least one protease inhibitor. Your viral load must be between 5,000 and 50,000 copies/ml after 6 months of continuous treatment with that drug combination.
* Agree to use a barrier method of birth control (such as condoms) during the study.
Exclusion Criteria
You will not be eligible for this study if you:
* Have a history of certain serious medical conditions, including pancreatitis, neuropathy, untreated seizures, or AIDS-related cancers, except Kaposi's sarcoma (KS).
* Are enrolled in another anti-HIV drug study while participating in this study.
* Have ever taken NNRTIs (such as NVP or MKC-442).
* Have ever taken ddI or d4T.
* Have taken certain medications within 30 days prior to study entry, including medications that affect your immune system (such as corticosteroids, interleukin-2, or interferon).
* Abuse alcohol or drugs.
* Have received chemotherapy or radiation therapy within 30 days prior to study entry. (Local radiation therapy is allowed.)
* Are allergic to any of the study drugs.
* Are pregnant or breast-feeding.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00002418
Study Brief:
Protocol Section:
NCT00002418